Axsome Therapeutics (AXSM) Other Non-Current Liabilities (2017 - 2026)

Axsome Therapeutics has disclosed Other Non-Current Liabilities across 7 years of filings, most recently posting $73.7 million for Q1 2026.

• Other Non-Current Liabilities for Q1 2026 came in at $73.7 million, down 18.61% year-over-year; the trailing twelve-month figure through Mar 2026 was $73.7 million (down 18.61% YoY), and the FY2025 annual result was $77.5 million, down 15.42% from the prior year.
• Other Non-Current Liabilities came in at $73.7 million for Q1 2026 at Axsome Therapeutics, down from $77.5 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $91.7 million in Q4 2024 to a low of $27.4 million in Q3 2022.
• The 5-year median for Other Non-Current Liabilities is $71.6 million (2023), against an average of $61.3 million.
• Across the five-year window, Other Non-Current Liabilities jumped 163.01% in 2024 and decreased 18.61% in 2026, its largest moves.
• Axsome Therapeutics' Other Non-Current Liabilities stood at $31.1 million in 2022, then jumped by 135.69% to $73.3 million in 2023, then grew by 25.08% to $91.7 million in 2024, then fell by 15.42% to $77.5 million in 2025, then fell by 4.91% to $73.7 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $73.7 million (Q1 2026), $77.5 million (Q4 2025), and $89.9 million (Q3 2025), per Business Quant data.